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ABSTRACT
Background
Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50
y of age in at least three continents. Choroidal neovascularization (CNV) is the process by which
abnormal blood vessels develop underneath the retina. CNV develops in 10% of patients with
AMD but accounts for up to 90% of the blindness from AMD.
Although the precise etiology of CNV in AMD remains unknown, the macrophage
component of the inflammatory response, which has been shown to promote tumor growth
and support atherosclerotic plaque formation, is thought to stimulate aberrant angiogenesis in
blinding eye diseases. The current theory is that macrophage infiltration promotes the
development of neovascularization in CNV.
Methods and Findings
We examined the role of macrophages in a mouse model of CNV. IL-10
 /  mice, which have
increased inflammation in response to diverse stimuli, have significantly reduced CNV with
increased macrophage infiltrates compared to wild type. Prevention of macrophage entry into
the eye promoted neovascularization while direct injection of macrophages significantly
inhibited CNV. Inhibition by macrophages was mediated by the TNF family death molecule Fas
ligand (CD95-ligand).
Conclusions
Immune vascular interactions can be highly complex. Normal macrophage function is critical
in controlling pathologic neovascularization in the eye. IL-10 regulates macrophage activity in
the eye and is an attractive therapeutic target in order to suppress or inhibit CNV in AMD that
can otherwise lead to blindness.
The Editors’ Summary of this article follows the references.
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Inﬂammation in response to insult and injury can stimulate
immunity and promote healing. However, recent work has
focused on the role of chronic inﬂammation in the develop-
ment of pathologic processes such as cancer, heart disease,
and eye disorders. The macrophage component of inﬂam-
mation has received attention because of macrophage
production of proangiogenic and proinﬂammatory molecules
that can fuel disease progression. In cancer, chronic
inﬂammation has been demonstrated within tumor foci,
and a number of studies suggest that tumor-associated
macrophages promote the growth, proliferation, and meta-
stasis of neoplastic cells as well as stimulate neovasculariza-
tion, leading to tumor progression [1,2]. Recent research in
heart disease has shown that inﬂammation plays a key role in
atherosclerosis. Immune cells have been shown to dominate
early atherosclerotic lesions, and molecules produced by
these cells accelerate progression of the disease [3].
Recent studies of the blinding eye disorder age-related
macular degeneration (AMD) also suggest a role for inﬂam-
mation, speciﬁcally macrophages, in promoting this disease
[4,5]. AMD is a progressive disease that causes irreversible
visual impairment and blindness in nearly 50 million people
globally [6,7]. Current estimates of patients affected with
AMD are higher than those of patients affected by Alzheimer
disease [8]. Although both geographic atrophy and neo-
vascularization represent advanced forms of AMD, neo-
vascular AMD is the more aggressive form and accounts for
almost 90% of blindness from this disease. It is characterized
by choroidal neovascularization (CNV), which is the develop-
ment of abnormal blood vessels underneath the retina.
Evidence for a disease-promoting role for macrophages in
neovascular AMD derives from two sources. First, studies in a
mouse model showed that systemic depletion of macrophages
using clodronate-ﬁlled liposomes blocked neovascularization
[4,5]. Second, certain single nucleotide polymorphisms in
complement factor H are observed in a signiﬁcantly higher
percentage of patients with AMD [9–12]. These data, along
with the discovery of complement factor H in AMD lesions
[10], have been interpreted to suggest that inﬂammation
promotes CNV.
Other recent studies suggest that macrophages may be anti-
angiogenic. Mice lacking a macrophage recruitment chemo-
kine (ccl-2) had spontaneous CNV [13], suggesting that when
macrophages could not be recruited to the eye, animals were
more prone to develop CNV. Another study showed that
macrophages are essential to the regression of abnormal
vasculature in the anterior segment of the eye [14]. Thus, the
role of macrophages in pathogenic neovascularization still
remains controversial.
Our study was designed to directly examine the complex
role of macrophages in an established mouse model.
Although the murine laser model is only a surrogate acute
injury model for AMD—which is a chronic disease—it has
been remarkably successful in predicting therapies that have
since proven to be efﬁcacious in the treatment of AMD
[15,16]. It has been also been extremely accurate in revealing
the pathophysiology of CNV, the sine qua non of neovascular
AMD [4,5,17,18]. Photodynamic therapy, the ﬁrst treatment
for CNV in AMD approved by regulatory agencies in the
United States, Europe, Australia, and Japan, was initially
examined and proven to be efﬁcacious in an animal model of
laser-induced CNV [15,19]. The ﬁrst human anti-VEGF
therapy for CNV in AMD was approved by the United States
Food and Drug Administration in 2005. The efﬁcacy of anti-
VEGF therapy in ocular neovascularization was initially
studied in an animal laser model and was then tested in two
large, randomized double-masked human clinical trials that
led to the US Food and Drug Administration approval of
anti-VEGF therapy for CNV in AMD [16,20]. In a laser-
induced mouse model, pigment-epithelium-derived factor
was demonstrated to inhibit CNV [21]. The same team of
investigators has since completed a phase I trial of adeno-
associated virus– pigment-epithelium-derived factor admin-
istered intravitreally in patients with CNV from AMD [22]. A
preponderance of evidence in the peer-reviewed literature
demonstrates that the laser model is a reliable surrogate for
understanding the pathophysiology of CNV in AMD. In
addition, it has proven to be an excellent model for testing
molecules and compounds that successfully treat CNV. The
injury to the retinal pigment epithelium (RPE) in AMD is a
chronic phenomenon; nevertheless, the laser-mediated injury
to the RPE in the mouse model, although acute, might
simulate an accelerated phenotype of the chronic disease
process. In this paper, we examine the role of innate
immunity, speciﬁcally macrophage-mediated immunity, in
regulating angiogenesis in the eye. We investigate the
complex role of macrophages in regulating angiogenesis in
an animal model of the human disease AMD and attempt to
understand the pathophysiologic mechanisms of CNV that
lead to blindness in AMD.
Methods
Mouse Strains
C57/BL6 (B6), B6-IL-10
 / , B6-gld, and B6-lpr mice were
purchased from Jackson Laboratory (Bar Harbor, Maine,
United States). All mouse experiments contained 3–5 mice
and were repeated at least three times with similar results. All
work was carried out in accordance with Association for
Research in Vision and Ophthalmology guidelines (http://
www.arvo.org/eweb/dynamicpage.aspx?site¼arvo2&webcode¼
AnimalsResearch).
Laser-Induced Murine Model of CNV
CNV was induced by rupture of the RPE and underlying
Bruch’s membrane with a krypton laser in 5- to 7-wk-old mice
as described [17,18]. Brieﬂy, four laser spots were placed in
each fundus in the peripapillary area using a Krypton Red
Laser (614 nm, 50 lm, 0.05 s, 200 mW). After 7 d, the animals
were perfused with 3% FITC-conjugated high-molecular-
weight dextran (2,000 kDa). A dissecting microscope was used
to remove the cornea and lens and gently separate the retina
from the underlying choroid and sclera. Microscissors were
used to make four radial incisions in the sclero-choroidal
eyecup in order to prepare choroidal ﬂat mounts on glass
slides. The tissues were incubated in 4% paraformaldehyde
for 45 min and washed three times with 3% bovine serum
albumin. The tissues were then counter-stained with Cy-3-
conjugated anti-mouse elastin antibody for 1 h and washed
three times with 3% bovine serum albumin. CNV was
identiﬁed as FITC-perfused vessels above the plane of Bruch’s
membrane on confocal microscopy. Images were captured in
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Macrophages in AMDa three-dimensional stacked fashion for volumetric analysis
by Metamorph imaging software (Universal Imaging, Sunny-
vale, California, United States). Data were recorded as volume
of CNV (microns
3) 6 standard error. CNV volumes for all
eyes in a treatment group were averaged and compared
individually to controls using Student’s t test, which has been
utilized in similar CNV studies [4,18]. CNV grading was
performed in a masked manner, where the individual groups
were coded with letters and then presented to the grader for
confocal microscopy and quantitative analysis of CNV.
Cytokine and Antibody Injections
Rat anti-mouse monoclonal antibodies to IL-10 (JES5.2A5)
and an isotype-matched (IgG2b) antibody were purchased
from Genzyme (Cambridge, Massachusetts, United States).
Mice received intravenous injections (500 lg) 1 d prior to
laser photocoagulation (day  1) as described previously [23].
Antibody injections were repeated on day 0 (day of laser) and
day 1, prior to harvesting of the eyes on day 7 for analysis of
CNV. Recombinant mouse IL-10 was purchased from BD
Biosciences (San Jose, California, United States). Five micro-
liters (100 ng) was injected into the vitreous cavity of mouse
eyes with a 33-gauge needle ﬁtted to a Hamilton syringe on
day 0 or 3 after laser treatment. Anti-CD11b (5C6), anti-F4/80
(C1;A3–1), and the isotype control (IgG2b) were purchased
from Serotec (Raleigh, North Carolina, United States). We
injected 500 lg of each antibody on days  1, 0, and 1.
Biotinylated anti–Fas ligand (FasL) (MFL-3) and Strepavidin-
FITC for ﬂow cytometry were purchased from BD Bioscien-
ces.
Immunohistochemistry
Sclero-choroidal ﬂat mounts were prepared 7 d after laser
treatment. PE-conjugated anti-CD11b antibody (1:100) or
isotype-matched control antibody (BD Biosciences) was used
to stain the mounts for 1 h at room temperature; the mounts
were then washed with PBS three times and analyzed by 3-D
confocal microscopy. Numbers of macrophages (CD11b
þ)
were counted per lesion (per 203 ﬁeld centered on the laser
lesion), and average numbers were represented. Lesions in
ﬂat mounts were also analyzed for neutrophils with PE-
conjugated anti-Gr-1 antibody, for dendritic cells with PE-
conjugated anti-CD11c, and for T cells with PE-conjugated
CD3 antibody (BD Biosciences). PE-conjugated F4/80 anti-
body (Caltag Laboratories, Burlingame, California, United
States) was also used to stain macrophages. PE-conjugated
anti-IL-10 antibody (1:100) and isotype control were pur-
chased commercially (BD Biosciences) and used for staining
parafﬁn-sectioned eyes as described above.
Bone Marrow Culture
Cells for intravitreal injections were prepared from bone
marrow culture and spleen. Bone marrow was isolated from
proximal limb bones as described previously [24]. Brieﬂy, all
muscle tissue was removed from the bones and the bones
were washed in 70% alcohol for 5 s prior to two washes in
PBS. The ends of the bones were cut with scissors and the
marrow harvested by using a syringe and 25-gauge needle to
ﬂush the bones with complete RPMI. Then 2 3 10
6 cells were
cultured for 10 d in 10 ml of complete RPMI and 1,000 U/ml
GM-CSF in 100-mm petri dishes. On day 3 and 6, an
additional 500 U/ml and 1,000 U/ml GM-CSF were added,
respectively. On day 10, the non-adherent cells containing
dendritic cells were discarded. The adherent cells were
mechanically removed and harvested with a cell scraper.
CD11b
þ cells were then isolated by positive selection (see
below).
Positive Selection Using Spleen Cells
CD11b
þ and F4/80
þ macrophages were puriﬁed from
dissociated mouse spleen cells or GM-CSF-cultured macro-
phages using the PE-positive selection kit (SpinSep, StemCell
Technologies, http://www.stemcell.com). CD3
þ Tc e l l so r
CD11c
þ dendritic cells were also isolated by the same
protocol. Cell purity was greater than 90% by ﬂow cytometry.
Cells were injected into the vitreous cavity of eyes of mice
using a 33-gauge Hamilton needle on the same day as laser
treatment. Control mice were injected with PBS.
Transgenic Mice
VMD2-IL-10 transgenic (Tg) mice were constructed to
overexpress IL-10 in RPE cells. VMD2 (Bestrophin) localizes
to the basolateral plasma membrane of the RPE [25] (pVMD2-
placF was provided by Noriko Ezumi, Johns Hopkins Medical
School). We removed the VMD2 promoter and cloned it into
the pCI plasmid (Promega, Madison, Wisconsin, United
States), replacing the CMV promoter, and then placed the
IL-10 ORF downstream. VMD2-FN-14 was made by replacing
the IL-10 ORF with the FN-14 ORF [26]. Tg mice were
produced by injecting fertilized mouse oocytes with trans-
gene DNA by standard protocols in the Washington
University Department of Ophthalmology and Visual Science
Molecular Biology Core facility. Founders were screened by
PCR and used for breeding. IL-10 expression was veriﬁed by
RT-PCR and immunohistochemistry. Biomicroscopic exami-
nation of the anterior and posterior segments of the eye and
histopathologic analysis of ocular tissues showed no overt
abnormalities. Such mice are viable and have shown normal
life spans compared to littermate controls (data not shown).
Macrophage Activation and Apoptosis Assay
Puriﬁed CD11b-F4/80 macrophages were placed into 96-
well ﬂat-bottom tissue culture plates (1 3 10
5 per well). Cells
were treated with lipopolysaccharide (LPS) (0.1 lg/ml) or
necrotic retinal cells for 3 h at 37 8C and 5% CO2 in complete
RPMI. L1210-Fas target cells (2 3 10
4 cells labeled with
3H-
thymidine) were added and the plates incubated for an
additional 16–20 h. Cells were harvested by ﬁltration through
glass ﬁber ﬁlters (Packard Instruments, Meriden, Connecticut,
United States) using a Filtermate 96-cell harvester (Packard
Instruments) and counted on a microplate scintillation
counter (Packard Instruments). Data were expressed as
percent cell death, calculated as 100 3 (counts per minute
from L1210-Fas alone – counts per minute of L1210-Fas
þ
macrophages)/counts per minute from L1210-Fas alone.
Preparation of Necrotic Retinal Cells
NecroticretinalcellswerepreparedfromB6mice.Eyeswere
removed from euthanized mice and dissected in RPMI
complete medium. Anterior segment and lens were removed
anddiscarded.Theneurosensoryretinawasgentlypeeledfrom
thechoroidwithﬁne-tipforcepsandgroundbetweentwoglass
slides. Cells in each retina were counted and cell number
adjusted to 5 3 10
7 per microliter. The retina was placed in
RPMI complete medium and subjected to four freeze/thaw
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was added per well of CD11b
þ-F4/80
þmacrophages.
Statistics
Student’s t test was used to perform statistics on all
experiments in the study, as described previously [17,18].
Individual numeric values were imported into the statistical
package (SigmaPlot for Windows, 2002 version) to compute
the p-value in order to determine signiﬁcance. A p-value of
less than 0.05 was considered to be signiﬁcant.
Results
IL-10 Promotes CNV
CNV in the mouse model is induced by disruption of the
RPE and underlying Bruch’s membrane with a krypton laser
[17,18]. Following laser treatment of the eye, blood vessels
penetrate the subretinal space, forming neovascular com-
plexes. The volume of these complexes is indicative of the
extent of new vessel growth (i.e., CNV). Values are easily
compared among groups in the same experiment. Although
only a surrogate for the human disease, the mouse model has
been used extensively to study the pathogenesis of exper-
imental neovascularization. The model has also been used in
preclinical trials for testing potential therapies for AMD that
have since proven effective in preventing vision loss [16,27].
We explored the role of inﬂammation by examining the
induction of CNV in IL-10
 /  mice. IL-10 is an anti-
inﬂammatory cytokine that inhibits T cell and macrophage
functions. It is a potent inhibitor of cytokine and chemokine
production, including a number of molecules known to
attract monocytes and macrophages to sites of inﬂammation.
The absence of IL-10 typically results in substantial increases
in inﬂammation at multiple sites following diverse stimuli
[23,28]. If the current hypothesis is correct, we would expect
increased inﬂammation and increased CNV in IL-10
 /  mice.
In comparing the volume of the neovascular complexes in IL-
10
 /  mice and-wild type (wt) B6 mice 7 d following laser
treatment, we found that mice lacking IL-10 had signiﬁcantly
decreased new vessel growth (Figure 1A). Systemic neutrali-
zation of IL-10 in wt B6 mice also signiﬁcantly diminished
CNV (Figure 1B), recapitulating the effect of the targeted
deletion of the IL-10 gene. Representative lesions from a B6
eye (Figure 1C) and an IL-10
 /  eye (Figure 1D) show
profound differences in CNV. Since IL-10 is made exclusively
by hematopoietic cells [28], it is not surprising that bone-
marrow-derived cells were identiﬁed as the source of IL-10 in
this model (Figure S1).
IL-10 Inhibits Recruitment of Macrophages to
Neovascular Complexes
The effects of IL-10 in this system could be direct, where
IL-10 inﬂuences endothelial cell function, or they could be
the result of the hyperinﬂammatory response that is
characteristic of IL-10-deﬁcient animals. We have been
unable to show an effect of IL-10 on vascular endothelial
cell proliferation or tube formation in vitro (data not shown),
and we have been unsuccessful in identifying IL-10 receptors
on vascular endothelial cells. Consequently, we tested
whether our observations in IL-10
 /  mice and wt mice
receiving anti-IL-10 were related to the increased inﬂamma-
tory phenotype observed in these animals. Examination of
the neovascular complexes in wt mice (Figure 2A), IL-10
 / 
mice (Figure 2B), and wt mice that were treated with
neutralizing anti-IL-10 (Figure 2C) revealed signiﬁcantly
more CD11b
þ cells in IL-10
 /  mice and wt mice treated with
neutralizing anti-IL-10 than in wt controls. Quantitation of
CD11b
þ cells in CNV lesions on day 7 conﬁrmed that there
are substantial increases in the number of these cells when IL-
10 is not present (Figure 2D). Immunohistochemical stains for
other CD11b
þ cells such as dendritic cells (CD11c) and
neutrophils (Gr-1) were negative, as were stains for T cells
(CD3) (data not shown). Immunostaining for CD11b and F4/
80 (Figure 2E) conﬁrmed that these inﬁltrating cells were
macrophages. While these data are consistent with the
hyperinﬂammatory state observed in the absence of IL-10,
they are not consistent with the idea that macrophages
promote CNV. Since mice with low amounts of CNV had
increased inﬁltration of CD11b
þ-F4/80
þ inﬂammatory cells
and a paucity of other immune cells, a more likely
explanation is that CD11b
þ-F4/80
þ macrophages are either
inhibiting blood vessel formation in the retina or promoting
vascular endothelial cell death.
Inhibiting Macrophage Recruitment Promotes CNV
We directly tested this idea with three types of experi-
ments. First, we used systemic injection of anti-CD11b or
anti-F4/80, treatments known to prevent entry of macro-
phages into tissue [29]. Figure 3A shows that depletion of
CD11b
þ cells with anti-CD11b as well as depletion of
macrophages with anti-F4/80 led to signiﬁcantly increased
neovascularization. Examination of the lesions in treated
mice revealed that both treatments abolished the migration
of macrophages into the laser lesions (data not shown). This
ﬁnding further substantiates that the presence of macro-
phages inhibits angiogenesis in the retina.
Next, the effect of intraocular IL-10 on CNV was explored
byadministering IL-10 (100ng) directly intothe eye of IL-10
 / 
mice. This resulted in a signiﬁcant increase in neovasculari-
zation that approached control levels (Figure 3B), with
injection of IL-10 on day 3 being more effective than
injection on day 0 (day of laser treatment). Thus, injection
of IL-10, which prevents inﬂammatory cell recruitment to
sites of inﬂammation [23,28], increased the level of CNV.
Based on these ﬁndings, we hypothesized that high levels of
IL-10 would prevent macrophage entry into the eye, resulting
in increased pathologic CNV. To test this idea, we developed
a Tg mouse overexpressing IL-10 in the RPE using the human
VMD2 promoter. These IL-10 Tg mice (or VMD2-IL-10)
expressed high levels of secreted IL-10 in the retina (Figure
3D) compared to transgene-negative mice (Figure 3C), but
had completely normal retinal architecture (Figure 3E). When
CNV was induced by laser treatment (Figure 3F), neo-
vascularization was substantially elevated over that in con-
trols. In addition, VMD2-IL-10 Tg mice did not show
macrophage inﬁltrates in the CNV lesions (data not shown).
Thus, direct injection of IL-10 and Tg overexpression of IL-10
both augmented new vessel formation. We conclude from
these experiments (Figures 2 and 3) that inhibition of
macrophage recruitment leads to increased levels of CNV.
Macrophages Directly Inhibit CNV
We directly tested whether macrophages inhibited CNV by
injecting cells into the vitreous cavity at the time of laser
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þ cells
obtained from bone marrow cultures signiﬁcantly reduced
CNV. Inhibition was observed with injection of 1310
5 and 5
3 10
5 cells. CD11b
þ cells obtained from spleen by positive
selection (.90% F4/80
þ; data not shown) also signiﬁcantly
inhibited CNV (Figure 4B), while splenic CD11c
þ (dendritic)
and CD3
þ (T cells) were not effective. These data further
support the idea that macrophages inhibit, rather than
promote, CNV. The effect is attributable to macrophages
and not dendritic cells as CD11c
þ dendritic cells and T cells
failed to inhibit CNV.
Macrophages Inhibit CNV via FasL-Mediated Cell Death
Inhibition of neovascularization by macrophages could be
mediated by a direct effect of the cells on the developing
vessels (via contact or through paracrine mechanisms), or it
could be the result of a secondary effect of these cells on
blood vessel formation through other resident or inﬁltrating
cells. CD95/CD95L interactions are known to regulate vessel
growth in the eye in the current model [17]. This regulation
operates through the interaction of CD95L with the Fas
antigen (CD95) on the choroidal blood vessels induced to
Figure 1. IL-10 and Neovascularization (CNV)
(A and B) CNV was induced in IL-10
 /  (volume of the neovascular complex: 829.6 6 225.7 lm
3) and B6 (IL-10
þ/þ; 8,830.7 6 1,130.3 lm
3) mice (A) and
B6 mice injected on days 0, 3, and 5 with anti-IL-10 (10,115.3 6 850.5 lm
3) or isotype control antibody (IgG2b; 33,602.3 6 317.4 lm
3) (B). Asterisks
indicate values significantly different from control; p-values given in parentheses are based on Student’s t test performed as described [17,18].
(C and D) Seven days following laser treatment, the volumes of the neovascular complexes (green) were determined by confocal microscopy. Shown is
representative CNV in a B6 eye (C) and an IL-10
 /  eye (D).
DOI: 10.1371/journal.pmed.0030310.g001
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Macrophages in AMDgrow by laser treatment. The CD95/CD95L pathway was
examined by injecting puriﬁed CD11b
þ cells from lpr (CD95-
deﬁcient), gld (CD95L-deﬁcient), or wt (B6) mice into the
vitreous to assess the effect on vessel formation. The results in
Figure 5A show that CD11b
þ cells lacking functional CD95L
(gld) did not inhibit CNV. Thus, CD95L derived from CD11b
þ
cells is responsible for inhibiting new vessel formation. This
effect is not due to the inability of gld macrophages to home
to the laser lesion after injection since there was no
difference in the number of carboxyﬂuorescein diacetate
succinimidyl ester (CFSE)–labeled wt or gld macrophages per
lesion when they were examined 3 d after injection (Figure
S2).
Macrophages are known to both promote and inhibit
inﬂammatory responses, but they are not typically FasL
þ
unless stimulated [30]. This suggests that activation (or at least
interaction) with the damaged retinal tissue might promote
CD95L expression, leading to acquisition of killing function.
CD11b
þ cells puriﬁed from spleen were subjected to necrotic
cells (from the retina) or LPS and then tested for their ability
to kill CD95
þtargets. As shown in Figure 5B, cells fed necrotic
cells or treated with LPS were able to kill CD95
þ targets. This
was through upregulation of CD95L on macrophages by both
stimuli (Figure 5C).
Discussion
Our data show that macrophages are protective against the
development of CNV in the eye and that IL-10 regulates
macrophage function. This ﬁnding suggests that in AMD a
functioning immune system is important in preventing
blindness from this disease. Since current treatments limit
vision loss but are not speciﬁcally designed to prevent or
reverse CNV, our results also suggest a novel approach to the
design of therapies.
Inﬂammation, speciﬁcally macrophage inﬁltration, is
known to promote a number of pathologic processes
including cancer, heart disease, and eye disorders. The ability
of these cells to produce a variety of molecules that stimulate
blood vessel growth is thought to be an important component
in disease progression. However, macrophage function is
highly complex as these cells can also promote wound healing
[31,32] and control vessel growth during developmental
Figure 2. Cellular Infiltrates in CNV Lesions
(A–C) On day 7 following laser treatment, whole mount stains were performed to determine the cells present in the area of the neovascular complex.
Stains for CD11b were performed on (A) B6, (B) IL-10
 / , and (C) B6 mice treated with neutralizing anti-IL-10. Images were take by confocal microscopy
(magnification 2003) centered on the laser lesion.
(D) The number of CD11b
þ cells per lesion was counted (2003 high-power field centered on the laser lesion) (B6, 6.3 6 0.9; IL10
 / , 22.6 6 2.1; B6 þ
anti-IL10, 22.5 6 2.5). Asterisks indicate values significantly different from control.
(E) Dual staining was performed on day 7 following laser treatment using FITC-conjugated anti-CD11b (green) and PE-conjugated anti-F4/80 (red)
(magnification 4003).
DOI: 10.1371/journal.pmed.0030310.g002
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Macrophages in AMDprocesses [14]. Our results demonstrate a potentially new role
for macrophages in blinding eye disorders, where macro-
phages may not be proangiogenic but function to limit the
spread of choroidal blood vessels in the eye. This effect on
CNV has implications for neovascular AMD, where CNV is
the major pathogenic factor.
Advanced AMD that leads to severe visual loss affects
almost 2 million people in the United States [33]. By 2020, the
number of patients with all stages of AMD in the industrial-
ized world is expected to increase by about 50%. AMD now
accounts for over 40% of blindness among the institution-
alized elderly [33,34]. Patients with advanced AMD rate their
quality of life lower than patients with AIDS and dialysis-
dependent renal failure [35,36]. Current treatments are
designed to limit further visual loss, but these are only
marginally effective [16]. There is no treatment that can
Figure 3. Inhibition of Macrophage Infiltration Promotes CNV
(A) IL-10
 /  mice were injected with anti-CD11b (volume of the neovascular complex: 12,903.1 6 2,171.3 lm
3), anti-F4/80 (9,977.3 6 1,572.7 lm
3), or
control IgG (2,262.3 6 313.4 lm
3) on days  1, 0, and þ1. CNV volumes were determined on day 7.
(B) IL-10
 /  mice were injected in the vitreous with PBS (1,394 6 382.4 lm
3) or 100 ng of rIL-10 on day 0 (the day of laser treatment; 4,033.6 6 1,026.5
lm
3) or day 3 (6,949.8 6 1,475.5 lm
3).
(C and D) Cross-sections of the retinas of a control littermate (C) and a VMD2-IL-10 Tg mouse (D) stained with anti-IL-10 and examined by confocal
microscopy.
(E) Hematoxylin and eosin staining of the retina of a VMD2-IL-10 Tg mouse (magnification 2003).
(F) VMD2-IL-10 Tg mice (24,428.6 6 4,360.7 lm
3) and littermate controls (6,830.1 6 1,324.9 lm
3) were subjected to laser treatment and CNV volumes
were determined on day 7.
Asterisks indicate values significantly different from control; p-values are given in parentheses.
DOI: 10.1371/journal.pmed.0030310.g003
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Macrophages in AMDreverse the damage to vision. Consequently, insights into the
etiology of CNV associated with AMD, as described in this
report, add signiﬁcantly to the information needed to design
effective treatments.
While it is clear that the immune system can play a role in
neovascularization, there has been conﬂicting evidence
regarding the role of the immune system in neovascular
AMD. The most popular idea is that macrophages (and
inﬂammation) are proangiogenic. Studies suggesting this used
the laser model described here and systemically depleted
phagocytic cells by injection of the compound clodronate
encapsulated in liposomes [4,5]. Since systemic depletion of
phagocytes decreased the level of CNV, the authors con-
cluded that macrophages promote CNV. When we examined
this system, we found that liposomes can actually enter
developing endothelial cells found in the laser-induced
neovascular complexes (Figure S3). These ﬁndings, coupled
with the fact that liposomes are known to enter a wide variety
of other cells [37,38], suggest that the effects observed may be
due to the toxicity of the clodronate liposomes directly on
sprouting endothelial cells.
A recent study suggested that macrophages may be anti-
angiogenic. These authors demonstrated that mice lacking a
macrophage recruitment chemokine (ccl-2) had spontaneous
CNV [13]. Although these authors did not discuss the
possibility, this observation suggests that the inability to
recruit macrophages into the eye leads to the development of
CNV. Not only do our results support this idea, but we have
directly tested it in the laser model of CNV. Our study shows
that increased macrophage inﬂux inhibits CNV, while treat-
ments that prevent macrophage entry into the eye suppress
the anti-angiogenic response of macrophages. Data from our
study complement the natural history of AMD and the
etiology of inﬂammatory eye diseases in humans. Although
leukocytes including macrophages, lymphocytes, erythro-
cytes, and other cells of hematopoietic origin have been
isolated from samples of CNV and identiﬁed by immunohis-
tochemistry or electron microscopy, there is no conclusive
evidence about whether these cells are pro- or anti-
angiogenic [39–41]. The possibility remains that these cells
represent an epiphenomenon related to the growth of
abnormal blood vessels in the subretinal space. Our data
demonstrate a novel role for macrophages in the CNV lesions
that is of potential therapeutic relevance. Clinical observa-
tions show that CNV in uveitis patients, who have signiﬁcant
inﬂammation in the eye, is less aggressive [42]. Our ﬁndings
also complement recent evidence that macrophages are anti-
angiogenic during development [14] and in tumors [2]. Based
on this information and the data presented in this report we
conclude that inﬂammation may be protective.
Recent genetic-linkage-based evidence suggests the poten-
tial importance of complement factor H in AMD [9,11,12].
However, the lack of functional data leaves these important
observations still open to interpretation, as they are also
consistent with the idea that a healthy immune system (e.g.,
complement pathway) may actually protect against blindness.
We would suggest that one explanation for the linkage
between complement factor H and AMD might be that
polymorphisms that lead to increased AMD are associated
with reduced macrophage recruitment to the chorio-retinal
tissues. The elderly, who are at risk for the development of
AMD, are known to have compromised immune function [43].
Thus, a disabled macrophage response may be an additional
risk factor for the development of CNV and blindness. We
would further suggest that physiologic immune surveillance
and normal macrophage function are critical in controlling
pathologic neovascularization.
The pivotal role for IL-10 in this model is likely related to
the anti-inﬂammatory properties of the cytokine and its
ability to inhibit cytokines that attract macrophages [23,28].
We can ﬁnd no effect of IL-10 on endothelial cells (data not
shown). Increases in chemotactic cytokines would be pre-
dicted when IL-10 is not present, and one would expect that
the loss of cytokines that promote inﬁltration of monocytes
or macrophages would predispose to AMD.
Our studies also demonstrate that macrophages use FasL to
inhibit CNV. We have demonstrated previously that FasL
Figure 4. Injection of Macrophages Inhibits CNV
Cells obtained from bone marrow (BM) cultures (A) or spleen (B) were
purified by magnetic beads and injected into the vitreous cavity on the
day of laser treatment. Seven days later, the volume of the neovascular
complex was determined by confocal microscopy. Asterisks indicate
values significantly different from control; p-values given in parentheses
are based on Student’s t test.
(A) Volume of the neovascular complex for injection of PBS (14,470.9 6
1,636.4 lm
3), CD11b cells—1 3 10
5 cells (2,431.2 6 551.3 lm
3), and
CD11b cells—5 3 10
5 cells (5,274.2 6 772.5 lm
3).
(B) Volume of the neovascular complex for injection of PBS (12,857.9 6
1,094.9 lm
3), CD3 cells (14,960.5 6 2,502.0 lm
3), CD11b cells (4,135.1 6
714.4 lm
3), and CD11c cells (15,063.3 6 1,982.4 lm
3).
DOI: 10.1371/journal.pmed.0030310.g004
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Macrophages in AMDexpressed on RPE cells is important for the control of CNV
[17]: mice defective in the expression of FasL on RPE cells had
massive increases in CNV. We believe that our current
observations complement this ﬁnding, since we believe that
FasL on both RPE cells and macrophages is necessary. The
loss of FasL on RPE cells leads to substantial (5- to 8-fold)
increases in CNV [17], and we would not expect the few
macrophages that enter the lesion (10–20 per lesion) to be
able to control this high level of CNV even if they are FasL
þ.
When FasL is present on the RPE, as occurs in most
experiments, the CNV is more modest and then amenable
to control by the FasL
þ macrophages that inﬁltrate the
lesions. It should be noted that the role of macrophage-
expressed FasL was revealed only when we injected large
numbers of FasL
þ macrophage into the vitreous (1–5 3 10
5).
Therefore, we conclude that RPE-derived FasL and macro-
phage-derived FasL are important in controlling CNV.
Our data suggest potential sites for therapeutic interven-
tion in AMD. Since the absence of IL-10 results in increased
macrophage inﬂux and reduced neovascularization, novel
targeting therapies designed to inhibit local IL-10 function,
promote tissue-speciﬁc macrophage activity, and/or target
the CD95/CD95L pathway should be considered as treatments
for neovascular AMD. IL-10 activity in the eye can be
inhibited by local administration of neutralizing antibodies,
inhibitory RNA, or aptamers. Although the most immediate
application for this form of therapy would presumably be in
patients with preexisting CNV in order to limit or reverse
vision loss, long-term inhibition of IL-10 function in the eye
could potentially be used as preventive therapy in patients
with dry AMD who are at high risk for developing CNV. In
addition to demonstrating that IL-10 is an attractive
therapeutic target in AMD, we have also shown that the role
of macrophages in angiogenesis might be more complex than
previously suggested. The anti-angiogenic functions of
macrophages should be considered in evaluating any thera-
pies that might nonselectively neutralize all macrophage
effector function because of the potentially devastating
consequences on the disease process and vision in patients
with AMD.
Figure 5. Macrophages Inhibit CNV via CD95L
(A) CD11b
þ cells from B6, B6-lpr, and B6-gld mice were purified from spleen, and 1310
5 cells were injected into the vitreous cavity on the day of laser
induction of CNV. Seven days later, the volume of the neovascular complex was determined by confocal microscopy for PBS (11,786.4 6 1,907.3 lm
3),
B6 (2,084.6 6 874.8 lm
3), gld (15,824.9 6 1,483.6 lm
3), and lpr (5,443.9 6 542.1 lm
3). Asterisks indicate values significantly different from control.
(B) Purified CD11b
þ cells were cultured overnight with LPS or necrotic retina and tested for killing against L1210-Fas.
(C) The expression of CD95L in CD11b cells was determined by flow cytometry following overnight culture with LPS (dotted line) or necrotic retina (solid
line). The line with shading underneath represents untreated cells.
DOI: 10.1371/journal.pmed.0030310.g005
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Figure S1. Source of IL-10
Bone marrow chimeras were generated to test the source IL-10. IL-
10
 /  mice that were reconstituted with B6 bone marrow (BM)
(volume of the neovascular complex: 10,143.9 6 1,962.8 lm
3) showed
levels of CNV comparable to B6 mice (12,756.7 6 3,744.4 lm
3). In
contrast, B6 mice that were reconstituted with IL-10
 /  bone marrow
(3,292.7 6 632.9 lm
3) showed levels of CNV similar to IL-10
 /  mice
(3,758.7 6 1,259.3 lm
3). This ﬁnding demonstrates the source of IL-
10 is hematopoietic cells. Asterisks indicate values signiﬁcantly
different from control.
Found at DOI: 10.1371/journal.pmed.0030310.sg001 (445 KB TIF).
Figure S2. Homing of CFSE-Labeled Macrophages to CNV Lesions
Macrophages from B6-wt or B6-gld mice were labeled with CFSE and
injected into the vitreous cavity on the day of laser treatment. The
number of macrophages per laser lesion were counted on day 3 and
were not signiﬁcantly different for B6 and gld mice (9.5 6 1.4 and 7.6
6 2.0, respectively; p ¼ 0.24).
Found at DOI: 10.1371/journal.pmed.0030310.sg002 (593 KB TIF).
Figure S3. Green-Fluorescent-Protein-Labeled Liposomes in CNV
Lesions
Green-ﬂuorescent-protein-labeled liposomes were injected intra-
venously into B6-wt mice on the day of laser treatment. The presence
of liposomes in the developing blood vessels within the laser lesions
was analyzed on day 3. Shown is a representative lesion that
demonstrates detectable liposomes in the laser lesion.
Found at DOI: 10.1371/journal.pmed.0030310.sg003 (234 KB TIF).
Protocol S1. Additional Methods
Found at DOI: 10.1371/journal.pmed.0030310.sd001 (60 KB DOC).
Accession Numbers
The NCBI accession numbers for the mouse genes and gene products
discussed in this paper are Fas gene (NM_007987), Fas protein
(NP_032013), FasL gene (NM_010177), FasL protein (AAB33780),
IL-10 gene (NC_000067), and IL-10 protein (NP_034678).
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Editors’ Summary
Background. The most common cause of poor eyesight in later life in
the developed world is known as age-related macular degeneration
(AMD). The macula is the central part of the retina (the film-like
membrane at the back of the eye), which is the most sensitive and
important for sharp central vision. There are two types of advanced AMD:
so-called wet, or neovascular, AMD (neovascular means ‘‘new vessel’’)
and dry, or geographic atrophy, AMD (atrophy means ‘‘to waste away’’).
Wet AMD occurs when abnormal, fragile new blood vessels grow under
the macula behind the retina. These blood vessels often leak blood and
fluid, which lift the macula. Dry AMD occurs as the light-sensitive cells in
the macula (the rods and cones) break down. To study this disease
further, researchers use animal models. One such animal model is made
by using a laser to damage the back of the eye in a mouse, which causes
the formation of new vessels. Various treatments can then be tested to
see if they have any effect on the damage.
Why Was This Study Done? One theory about AMD is that the immune
system may be involved in determining how severe the damage at the
back of the eye is, and how much new vessel formation occurs. The
researchers wanted to look at the effect of the immune system on AMD,
in particular, the effect of one type of cell called a macrophage, and a
substance, IL-10, that is secreted from bone marrow cells and that affects
how these macrophages work.
What Did the Researchers Do and Find? The researchers used a mouse
strain in which IL-10 was absent, induced damage in the eyes that
mimicked AMD, and then looked at what role macrophages had in the
eye abnormalities. They found that in the eyes of mice that lacked IL-10,
there was reduced new vessel formation and increased numbers of
macrophages compared to mice that had normal amounts of IL-10. Also,
preventing macrophages from getting into the eyes of such mice by
injecting IL-10 into the eyes made the new vessel formation worse, while
direct injection of macrophages made it better.
What Do These Findings Mean? Although animal models cannot
completely replicate disease in humans, they can give us an idea of how
diseases might come about and suggest possible treatment strategies. It
is possible that inhibiting the effect of IL-10, or other strategies that
make macrophages more efficient in the eye, may be a useful treatment
for AMD. In a related Perspective (DOI: 10.1371/journal.pmed.0030364),
Susan Lightman and Virginia Calder discuss the findings further,
including suggesting new experiments that will need to be done as a
next step.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030310.
  MedlinePlus encyclopedia entry on macular degeneration
  National Institutes of Health Senior Health page of information on
AMD
  National Eye Institute AMD fact page
PLoS Medicine | www.plosmedicine.org August 2006 | Volume 3 | Issue 8 | e310 1381
Macrophages in AMD